See more : Ningbo Color Master Batch Co., Ltd. (301019.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Lannett Company, Inc. (LCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lannett Company, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Fastenal Company (FAS.DE) Income Statement Analysis – Financial Results
- Kokuyo Camlin Limited (KOKUYOCMLN.NS) Income Statement Analysis – Financial Results
- Fastned B.V. (FAST.AS) Income Statement Analysis – Financial Results
- OPTiM Corporation (OTPMF) Income Statement Analysis – Financial Results
- D&L Industries, Inc. (DALQF) Income Statement Analysis – Financial Results
Lannett Company, Inc. (LCI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lannett.com
About Lannett Company, Inc.
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 340.58M | 478.78M | 545.74M | 655.41M | 684.56M | 637.34M | 566.09M | 406.84M | 273.77M | 151.05M | 122.99M | 106.84M | 125.18M | 119.00M | 72.40M | 82.58M | 64.06M | 44.90M | 63.78M | 42.49M | 25.13M | 12.09M | 11.55M | 10.60M | 9.46M | 3.80M | 3.82M |
| Cost of Revenue | 307.41M | 403.19M | 380.52M | 411.80M | 395.86M | 332.13M | 256.00M | 100.48M | 119.36M | 93.63M | 84.04M | 83.52M | 83.84M | 73.76M | 54.08M | 57.39M | 33.90M | 31.42M | 26.86M | 16.26M | 8.45M | 6.53M | 7.89M | 6.60M | 6.12M | 2.64M | 1.87M |
| Gross Profit | 33.17M | 75.59M | 165.22M | 243.61M | 288.71M | 305.21M | 310.09M | 306.36M | 154.41M | 57.42M | 38.95M | 23.32M | 41.34M | 45.24M | 18.32M | 25.18M | 30.16M | 13.48M | 36.92M | 26.23M | 16.67M | 5.56M | 3.66M | 4.00M | 3.34M | 1.16M | 1.95M |
| Gross Profit Ratio | 9.74% | 15.79% | 30.27% | 37.17% | 42.17% | 47.89% | 54.78% | 75.30% | 56.40% | 38.01% | 31.67% | 21.83% | 33.02% | 38.02% | 25.31% | 30.50% | 47.08% | 30.03% | 57.89% | 61.73% | 66.36% | 45.95% | 31.70% | 37.74% | 35.33% | 30.64% | 51.10% |
| Research & Development | 22.36M | 24.17M | 29.98M | 38.81M | 29.20M | 42.07M | 45.05M | 30.34M | 27.71M | 16.25M | 11.84M | 8.59M | 11.25M | 8.43M | 5.17M | 7.46M | 8.10M | 6.27M | 5.90M | 2.58M | 1.75M | 1.40M | 730.65K | 900.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 82.20M | 73.48M | 0.00 | 49.53M | 38.61M | 22.41M | 20.19M | 15.91M | 17.38M | 26.06M | 16.79M | 14.13M | 11.80M | 9.19M | 8.86M | 4.34M | 3.30M | 2.01M | 1.36M | 1.20M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 81.02M | 68.08M | 79.47M | 87.65M | 82.20M | 73.48M | 68.33M | 49.53M | 38.61M | 22.41M | 20.19M | 15.91M | 17.38M | 26.06M | 16.79M | 14.13M | 11.80M | 9.19M | 8.86M | 4.34M | 3.30M | 2.01M | 1.36M | 1.20M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 178.00K | -1.66M | -840.00K | -2.02M | 47.62M | 99.22M | 68.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -230.57K | 9.55M | 1.80M | 51.66M | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 1.66M | 1.24M | 1.26M |
| Operating Expenses | 103.39M | 92.25M | 109.45M | 126.46M | 111.39M | 115.55M | 113.38M | 79.87M | 66.32M | 38.66M | 32.04M | 24.50M | 28.63M | 34.49M | 21.73M | 31.15M | 21.71M | 67.12M | 16.09M | 6.91M | 5.05M | 3.42M | 2.09M | 2.20M | 1.66M | 1.24M | 1.26M |
| Cost & Expenses | 410.80M | 495.44M | 489.97M | 538.25M | 507.25M | 447.68M | 369.38M | 180.35M | 185.68M | 132.30M | 116.08M | 108.01M | 112.46M | 108.24M | 75.81M | 88.54M | 55.61M | 98.54M | 42.95M | 23.17M | 13.50M | 9.95M | 9.98M | 8.80M | 7.78M | 3.87M | 3.13M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 425.00K | 295.00K | 116.00K | 142.00K | 90.99K | 62.33K | 209.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 57.98M | 53.83M | 66.85M | 84.62M | 85.63M | 89.42M | 65.94M | 207.00K | 130.00K | 251.00K | 273.00K | 214.52K | 275.87K | 321.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 178.00K | -1.66M | 56.31M | 55.59M | 55.12M | 55.34M | 33.43M | 5.58M | 5.98M | 6.20M | 5.74M | 4.98M | 4.89M | 5.10M | 5.23M | 4.47M | 3.97M | 6.97M | 2.51M | 982.19K | 789.30K | 767.05K | 678.63K | 600.00K | 369.37K | 206.69K | 204.27K |
| EBITDA | -176.27M | -18.32M | 54.94M | 115.14M | 191.84M | 145.28M | 161.47M | 233.14M | 96.07M | 27.07M | 12.56M | 4.45M | 17.80M | 16.05M | -464.71K | -1.46M | 12.50M | -46.85M | 23.32M | 19.98M | 11.97M | 3.60M | 1.56M | 1.50M | 1.25M | -582.65K | 341.33K |
| EBITDA Ratio | -20.57% | -3.83% | 10.07% | 17.57% | 28.02% | 22.79% | 28.52% | 57.31% | 35.09% | 17.92% | 10.21% | 4.17% | 14.22% | 13.48% | -0.64% | -1.76% | 19.51% | -104.35% | 36.56% | 47.04% | 47.64% | 29.81% | 13.53% | 14.15% | 13.15% | -15.33% | 8.94% |
| Operating Income | -70.22M | -16.66M | -1.37M | 59.54M | 129.70M | 86.45M | 130.76M | 226.49M | 88.09M | 18.76M | 6.91M | -994.95K | 13.03M | 10.78M | -5.43M | -5.96M | 8.45M | -53.64M | 20.83M | 19.32M | 11.63M | 2.14M | 1.58M | 1.80M | 1.68M | -72.12K | 691.34K |
| Operating Income Ratio | -20.62% | -3.48% | -0.25% | 9.08% | 18.95% | 13.56% | 23.10% | 55.67% | 32.18% | 12.42% | 5.62% | -0.93% | 10.41% | 9.06% | -7.50% | -7.22% | 13.20% | -119.46% | 32.66% | 45.46% | 46.27% | 17.69% | 13.63% | 16.98% | 17.75% | -1.90% | 18.10% |
| Total Other Income/Expenses | -163.71M | -286.19M | -47.25M | -405.79M | -78.60M | -85.90M | -68.58M | 935.00K | 1.93M | 1.93M | -292.00K | 293.58K | -208.95K | -112.56K | -213.23K | 43.33K | 76.18K | -185.84K | -21.20K | -314.60K | -446.22K | 698.11K | -690.26K | -900.00K | -804.32K | -78.76K | -554.27K |
| Income Before Tax | -233.92M | -302.85M | -48.63M | -346.25M | 51.09M | 550.00K | 62.18M | 227.42M | 90.02M | 20.69M | 6.62M | -701.37K | 12.82M | 10.67M | -5.64M | -5.92M | 8.53M | -53.83M | 20.81M | 19.00M | 11.18M | 2.84M | 884.77K | 900.00K | 875.72K | -150.88K | 137.07K |
| Income Before Tax Ratio | -68.68% | -63.25% | -8.91% | -52.83% | 7.46% | 0.09% | 10.98% | 55.90% | 32.88% | 13.69% | 5.38% | -0.66% | 10.24% | 8.96% | -7.79% | -7.17% | 13.32% | -119.87% | 32.63% | 44.72% | 44.50% | 23.47% | 7.66% | 8.49% | 9.25% | -3.97% | 3.59% |
| Income Tax Expense | -2.30M | 60.63M | -15.26M | -74.14M | 22.40M | 1.10M | 17.32M | 77.43M | 32.86M | 7.30M | 2.60M | -461.57K | 4.81M | 4.09M | -3.38M | 1.01M | 3.56M | -21.05M | 7.59M | 7.33M | 3.98M | 1.01M | -465.33K | -400.00K | -150.00K | -78.76K | -554.27K |
| Net Income | -231.62M | -363.48M | -33.37M | -272.11M | 28.69M | -581.00K | 44.78M | 149.92M | 57.10M | 13.32M | 3.95M | -276.90K | 7.82M | 6.53M | -2.32M | -6.93M | 4.97M | -32.78M | 13.22M | 11.67M | 7.20M | 1.83M | 1.35M | 1.30M | 1.03M | -789.34K | 137.07K |
| Net Income Ratio | -68.01% | -75.92% | -6.11% | -41.52% | 4.19% | -0.09% | 7.91% | 36.85% | 20.86% | 8.82% | 3.21% | -0.26% | 6.25% | 5.49% | -3.20% | -8.39% | 7.76% | -73.00% | 20.72% | 27.46% | 28.64% | 15.13% | 11.69% | 12.26% | 10.84% | -20.77% | 3.59% |
| EPS | -22.96 | -36.91 | -3.46 | -28.81 | 0.19 | 0.00 | 0.31 | 1.05 | 0.42 | 0.12 | 0.03 | 0.00 | 0.08 | 0.07 | -0.02 | -0.07 | 0.05 | -0.34 | 0.16 | 0.15 | 0.09 | 0.02 | 0.02 | 0.04 | 0.03 | -0.03 | 0.00 |
| EPS Diluted | -22.96 | -36.91 | -3.46 | -28.81 | 0.19 | 0.00 | 0.30 | 1.01 | 0.41 | 0.12 | 0.03 | 0.00 | 0.08 | 0.07 | -0.02 | -0.07 | 0.05 | -0.34 | 0.16 | 0.15 | 0.09 | 0.02 | 0.02 | 0.04 | 0.03 | -0.03 | 0.00 |
| Weighted Avg Shares Out | 10.09M | 9.85M | 9.65M | 9.44M | 152.65M | 147.25M | 145.77M | 143.31M | 134.65M | 113.87M | 113.05M | 107.03M | 98.98M | 97.79M | 96.91M | 95.57M | 94.65M | 96.41M | 83.91M | 80.46M | 79.96M | 91.50M | 79.24M | 31.20M | 30.77M | 31.24M | 31.24M |
| Weighted Avg Shares Out (Dil) | 10.09M | 9.85M | 9.65M | 9.44M | 152.65M | 147.25M | 149.56M | 148.51M | 140.77M | 115.77M | 113.63M | 107.03M | 100.80M | 98.35M | 96.91M | 95.57M | 94.65M | 96.41M | 83.91M | 80.46M | 79.96M | 91.50M | 79.24M | 31.20M | 30.77M | 31.24M | 79.24M |
Lannett To Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 3
Lannett Announces New $30 Million Revolving Credit Facility
Lannett Company, Inc. (LCI) CEO Tim Crew on Q1 2021 Results - Earnings Call Transcript
Lannett To Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call On Wednesday, November 4
Sensex , Nifty end higher but off day's high; Britannia, ONGC worst hit
Emkay Global sees a 22% upside in HCL Technologies , gives 'Buy' rating
Tech and More
HCL Tech beats expectations
Source: https://incomestatements.info
Category: Stock Reports